EDLB- Illumina Inc, OEM maintenance for the Illumina MiSeq i100 Plus Sequencer

The Centers for Disease Control and Prevention (CDC) is seeking a five-year sole source procurement for a maintenance agreement for its Illumina MiSeq i100 Plus Sequencer. This agreement, with an estimated cost of $68,862.65, will be awarded to Illumina, Inc., the original equipment manufacturer. The justification for this non-competitive action is based on the determination that Illumina is the only available source capable of providing the necessary OEM-certified maintenance, proprietary diagnostic software access, firmware updates, certified replacement parts, and manufacturer-authorized service support for this highly specialized scientific instrument. Market research confirmed Illumina's exclusive rights to proprietary technology, diagnostic software, and essential updates, with no authorized third-party providers identified. This sole source acquisition is crucial for maintaining the operational readiness and integrity of the sequencer, a mission-critical component of CDC’s PulseNet foodborne disease surveillance network.

The Centers for Disease Control and Prevention (CDC) intends to award a sole-source Firm-Fixed-Price contract to Illumina, Inc. for a maintenance agreement for their MiSeq i100 Plus Sequencer S/N: SH00687. This instrument is critical for CDC's PulseNet foodborne disease surveillance network, performing whole-genome sequencing of enteric pathogens. The comprehensive OEM maintenance and support agreement will provide preventative maintenance, technical support, software/firmware updates, replacement parts, repair services, and OEM-certified field service engineer support to ensure reliable operation. Illumina, Inc. is the sole source capable of providing these OEM-certified services, proprietary software, and certified parts. Interested organizations can submit capability statements by June 22, 2026, at 10:00 a.m. Eastern Time to dal3@cdc.gov for consideration, though the government reserves the right to proceed with a sole-source acquisition.